Earnings ESP for PRME is 0.0%. The company currently carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Shares of Prime Medicine (NASDAQ: PRME) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.

I rate Prime Medicine as a Hold due to its promising technology but significant cash burn and dilution risks. PRME's short-term liquidity is $162.9M. Read more here.

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...

Prime Medicine, Inc. (PRME – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Arthur ...

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered ...

Going by the price/book ratio, PRME’s shares currently trade at 2.67X, much lower than 4.74 for the industry and the company’s mean of 3.90. Image Source: Zacks Investment Research Investment ...

Shares of Prime Medicine(NASDAQ: PRME) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m. ET and was up as much as 17% earlier in the day. The move up comes as the ...

PRME Stock Earnings: Prime Medicine Misses EPS for Q2 2024. InvestorPlace. Aug. 8, 2024, 10:54 AM. ... as well as how a company stacks up to analyst estimates.